---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-058242"
form_type: "8-K"
ticker: "ATOS"
cik: "0001488039"
company_name: "ATOSSA THERAPEUTICS, INC."
filed_at: "2024-05-13T23:59:59+00:00"
generated_at: "2026-06-02T02:12:16.664313+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Atossa Q1 2024 net loss $5.9M; EVANGELINE 100% disease control at 24 weeks

## Summary
- Net loss of $5.9M (operating expenses $7.0M, interest income $1.1M); cash $84.0M, no debt.
- EVANGELINE study: 100% disease control rate, 37% avg lesion size reduction, 92% Ki-67 drop at 24 weeks.
- Initiated combination study of (Z)-endoxifen + abemaciclib in ER+/HER2- breast cancer (20 patients).
- I-SPY 2 Phase 2 trial fully enrolled; data readout expected in H2 2024.
- Appointed medical oncologist Dr. Tessa Cigler to Board of Directors.

## SEC filing metadata
- accession: 0000950170-24-058242
- form_type: 8-K
- ticker: ATOS
- cik: 0001488039
- company_name: ATOSSA THERAPEUTICS, INC.
- filed_at: 2024-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1488039/000095017024058242/0000950170-24-058242-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1488039/000095017024058242/atos-20240513.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-058242
- JSON: https://secwatch.observer/filing/0000950170-24-058242.json
- Plain text: https://secwatch.observer/filing/0000950170-24-058242.txt

## Key facts
- Earnings Releases
  ATOSSA THERAPEUTICS, INC. reported financial results for fiscal quarter ended March 31, 2024.
  - Period: fiscal quarter ended March 31, 2024
  - Result: reported results
  source text: On May 13, 2024, Atossa Therapeutics, Inc. (the “Company”) issued a press release announcing the quarter ended March 31, 2024 financial results and providing a Company update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1488039/000095017024058242/0000950170-24-058242-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.